tbuckley/cabot-search huggingface dataset:
Surgical Management
Authors: Alvin M. Cotlar
Journal: JAMA (1985)

The monumental task of preparing a comprehensive textbook of surgery in a single volume is successfully accomplished by the well-known Professor Selwyn Taylor and his distinguished associate editors. These British surgeons present a literary format that never neglects the basic and historical while including the most modern concepts of surgical diagnostic and therapeutic techniques. The book is divided into seven primary sections: (1) alimentary tract, (2) urogenital tract and transplantation, (3) heart, lungs, and blood vessels, (4) endocrine system, (5) tumors of the breast, head, and neck, (6) trauma and technique, and (7) patient care. These titles are misleading, since each section contains chapters on many subjects not suggested by section heading. The "Trauma and Technique" section, for example, includes comprehensive individual chapters on hand surgery, microsurgery, and inguinal hernia repair. Each of the 54 chapters is well organized and has a current bibliography. The book is lavishly illustrated with
In This Issue
Journal: Journal of Clinical Investigation (2009)

Cell type-specific nonviral gene therapyHemophilia A is an inherited bleeding disease caused by a lack of Factor VIII (FVIII).It had been hoped that gene therapy would provide a treatment breakthrough, but gene replacement strategies using viral vectors have been unsuccessful in clinical hemophilia trials.However, Kren and colleagues have developed a nonviral, cell type-specific gene-targeting system and used it to achieve long-term expression of FVIII in hemophilia A mice, markedly reducing disease severity (2086-2099).Using a dispersion atomization method, the authors generated nanocapsules coated in asialoorosomucoid (ASOR) or hyaluronan (HA) - ligands for cell-surface receptors expressed uniquely by hepatocytes and liver sinusoidal endothelial cells, respectively - and demonstrated their ability to target encapsulated plasmids in a cell type-specific manner.Of therapeutic interest, when hemophilia A mice were injected intravenously with HAcoated nanocapsules containing the Sleeping Beauty (SB) transposon in cis with the gene encoding B domain-deleted canine FVIII, they exhibited plasma FVIII activity almost identical to that of wild-type mice through 50 weeks.As the hemophilia phenotype was markedly improved by treatment, the authors hope this combination of technologies, the cell-specific nanocapsule delivery system and the SB transposon, might constitute a viable gene therapy approach for treating hemophilia A.
The Propaganda for Reform
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ANGINA PECTORIS.
Authors: JAMES DUDLEY MORGAN
Journal: JAMA (1899)

Pain is so seldom directly associated with serious diseases of the heart that most specialists and practitioners of medicine are wont to treat lightly a patient's anxious inquiry about the heart, and to dismiss the case with no particular guidance or injunction, as one having an imaginary or neurasthenic origin. Though it has been considerably over one hundred years—1768—since Herbenden gave the name of angina pectoris to a certain affection of the heart, which he declared must be distinguished from ordinary cardiac dyspnea, and a few years later Edward Jenner described some of the morbid conditions, which may be found in this disease, yet there is to-day no one certain and positively accepted statement of the cause of this sudden taking off of a human being, who may have previously complained but little, or not at all, of feeling badly. Since Herbenden's time nearly all medical writers and clinicians have
American Association of Immunologists Course in Advanced Immunology
Journal: JNCI Journal of the National Cancer Institute (1984)

American Association of Immunologists Course in Advanced Immunology Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 1, January 1984, Page 199, https://doi.org/10.1093/jnci/72.1.199-b Published: 01 January 1984
Screening for Cervical and Breast Cancer— Southeastern Kentucky
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery.
Authors: Nima Almassi, Tianming Gao, Byron Lee, Robert Stein, Georges-Pascal Haber, Moshe Chaim Ornstein, Brian I. Rini, Timothy D. Gilligan, Jorge A. Garcia, Andrew J. Stephenson, Petros Grivas
Journal: Journal of Clinical Oncology (2018)

457 Background: Neoadjuvant chemotherapy (NAC) is infrequently administered to patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy or segmental ureterectomy and its impact on pathologic outcomes unclear. We examine pathologic outcomes in patients with UTUC receiving NAC before extirpative surgery using a population-based cancer registry. Methods: Patients who underwent extirpative surgery for UTUC from 2006-2014 were identified from the National Cancer Database. Among patients with available clinicopathologic data, the incidence of pathologic down-staging, defined as a lesser pathologic compared to clinical stage, was compared between patients who did and did not receive NAC. A multivariable model was developed to identify predictors of pathologic down-staging. Results: 7,244 patients were identified with non-metastatic UTUC who underwent extirpative surgery in the study period. 260 patients (3.6%) received NAC, with the use of NAC increasing over time from 2.0% patients in 2006 to 7.1% of patients in 2014 (linear trend p &lt; 0.001). Clinical and pathologic staging data were available for 119 and 2904 patients who did and did not receive NAC, respectively. Thirty patients (25.2%) who received NAC experienced pathologic down-staging, compared to 52 patients (1.8%) who did not receive NAC (p &lt; 0.0001). On multivariable analysis, NAC was associated with a higher likelihood of pathologic down-staging (OR 10.2, 95% CI 5.4-19.3). Additional predictors of pathologic down-staging include a higher clinical T stage (p = 0.001) and African-American race (OR 2.7, 95% CI 1.1-6.6). Compared to renal pelvis UTUC, ureteral UTUC was associated with a similar likelihood of pathologic down-staging (OR 1.5, 95% CI 0.9-2.5). Conclusions: NAC is infrequently used among patients with UTUC undergoing extirpative surgery. A higher incidence of pathologic down-staging was observed among patients receiving NAC. These findings suggest clinical benefit of NAC with respect to pathologic outcomes in patients with UTUC and may help guide selection of patients for NAC prior to radical surgery until data from prospective studies becomes available.
Abstract Changes
Authors: Amos R. Koontz
Journal: JAMA (1961)

<h3>To the Editor:—</h3> Heartiest congratulations on your return to the old system of abstracts from the literature which was prevalent inThe Journalfor so many years. This consisted of the listing of all the subjects from important journals and the abstracting of a few of them, thus giving the reader a chance to know everything important that came out in the medical literature. As I earlier pointed out, no doctor can subscribe to all the journals, nor does he have time to go to the library and peruse all that he would like to. Your system gave him an opportunity to know what was being published so that, when he found a title he was interested in, he could get the appropriate journal from the library and read the article in full. You have recently, through the cooperation of other journals, begun publishing abstracts simultaneously with the publication of
Das Sputum.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma (KS): Implications for the Design of Therapeutic Trials in Patients With Advanced Symptomatic KS
Authors: Guglielmo Nasti, Umberto Tirelli
Journal: Journal of Clinical Oncology (2005)

The article by Dr Krown 1 provides very appropriate and timely considerations with regard to the management of patients with advanced, symptomatic, AIDS-related Kaposi's sarcoma (AIDS-KS) in the era of highly active antiretroviral therapy (HAART) and suggests, on the basis of a comprehensive review of the literature, that in T1 (according to the AIDS Clinical Trials Group [ACTG] staging classification) symptomatic KS patients, concomitant chemotherapy should be added to HAART without awaiting a response to HAART.Moreover, the author, referencing our study, 2 states that "T1 and T0 groupings have been associated with distinct survival distribution."In response, we would like to clarify our data as reported by Dr Krown.We believe that our data may help to better define which group of patients within the T1 category need a timely institution of chemotherapy concomitantly to HAART, and for which group it is too risky to await a possible response to HAART.In our study, we collected clinical and survival data from 211 patients with AIDS-KS enrolled in two prospective cohort studies beginning in 1996, the time when HAART became available in Italy, with the aim of validating the ACTG staging system for AIDS-KS in the HAART era.All patients received HAART.Our analysis identified two different risk categories: a good-risk group (T0S0, T1S0, and T0S1) and a poor-risk group (T1S1).The 3-year survival rate of patients with T1S1 was 53%, significantly lower than the 3-year survival rates of patients with T0S0, T1S0, and T0S1, which were 88%, 80%, and 81%, respectively (P ϭ .0001).Therefore, the T category alone does not provide an appropriate survival discrimination, as occurred in the pre-HAART period. 3When we considered only patients with pulmonary involvement (namely,Tp1) as compared with T1 patients without pulmonary disease (namely,Tp0), the 3-year survival rate was 46% for Tp1 and 77% for Tp0 patients (P ϭ .0002),indicating that patients with pulmonary involvement identify the group of patients with the poorest prognosis, independent of the other ACTG variables.Therefore, we believe that we were able to identify, within the T1 category, a specific subgroup of KS patients (ie, T1S1, Tp1) with an unfavorable survival rate in whom HAART and concomitant chemotherapy should be used.
Abnormal Response to Parathyroid Extract in Sarcoidosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiopulmonary Resuscitation
Authors: Robert E. Johnstone
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Recently,The Journalpublished "Standards for Cardiopulmonary Resuscitation and (CPR) Emergency Cardiac Care (ECC)" (227:833, 1974). Several practical points, often omitted in professional training, need emphasis. Effective CPR requires group organization. Resuscitation teaching usually consists of lectures and of practice in ventilating and compressing a dummy. Seldom is a "cardiac arrest" simulated; trainees must learn organization and performance techniques at real arrests. Efficiently delivered resuscitation, however, is as important as scientific knowledge. Group practices and preorganization are helpful. Since resuscitation of an arrested patient is perhaps the most dramatic scene in medicine, many hospital personnel are attracted to the scene. Most want to help, but after six to ten people arrive, additional people decrease efficiency. Resuscitation team members should include an anesthesiologist, a cardiologist, a pharmacist, and three or four others to bring equipment, compress the chest, start an intravenous infusion, inject drugs, and record events, but
Ecology and Medicine
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HBV Virology and Diagnostics
Journal: Hepatology (2013)

ters.The diagnosis of CHB infection was made on the basis of biochemical, serological and histological data, when available.Seventy and six percent of the patients were nucleos(t)ide naïve.Virological response was defined as undetectable serum HBV DNA level (<200 copy/ml) by COBAS Taqman (Roche Diagnostics, Mannheim, Germany).Safety issue was analyzed based on renal function.Results: Median age was 47.0 years.At baseline, 32% of the patients were HBeAg positive, 38% had cirrhosis, 201 patients were treated with ETV and 310 were treated with TDF based on the discretion of investigators.There were no significant differences in terms of the baseline characteristics observed between two treatment groups except initial higher serum AST (p=0.001),GGT (p=0.007) and HBV DNA levels (p=0.001) in ETV treatment group.Overall virological response rates in ETV and TDF treatment groups were 60% vs 58% (p>0.05),81% vs 70% (p=0.017),84% vs 77% (p>0.05) and 86% vs 84% (p>0.05) at 24, 48, 72 and 96 weeks, respectively.In NUC-naïve group, response rates were 59% vs 59% (p>0.05),81% vs 72% (p=0.042),84% vs 78% (p>0.05) and 86% vs 85% (p>0.05) at 24, 48, 72 and 96 weeks, respectively.With logistic regression analysis, after adjusted age and gender, ETV treatment (p=0.039,OR: 1.72) and HBeAg negativity (p=<0.001,OR: 3.69) were predictive factors for undetectable HBV DNA at week 48.Primary non response (< 1 log10 decrease) at week 24 was observed in 2% (2 ETV, 7 TDF) and partial virological response at week 48 in 25% of the patients (19% ETV vs 29% TDF, p=0.011).HBeAg loss was achieved in 23 of HBeAg positive patients.The cumulative probability of HBeAg loss was 10.9% and 20.4% at weeks 48 and 96, respectively.HBsAg loss was achieved in 2 patients.Hepatocellular carcinoma developed in 10 cirrhotic patients.Both treatments were well tolerated, no serious adverse event was observed.From baseline to the end of the 96 weeks, no significant difference in terms of the serum creatinine levels was observed between two treatment groups (median 0.87 mg/dL vs 0.87 mg/dL in ETV group and 0.82 mg/dL vs 0.84 mg/dL in TDF group (p>0.05).Conclusions: This study confirms that ETV and TDF suppressed HBV viral replication in CHB patients with/without cirrhosis in clinical practice.Both drugs are safe and tolerable in such patients.
Lactose Intolerance as Cause of Steatorrhea in an Adult- F. Kern, Jr., J. E. Struthers, Jr., and W. L. Attwood
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dean of New York Medical College Dies
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Steadfast
Authors: Juliet Hubbell
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal